CRANFIT Tablets (Cranberry + D-mannose)

Introduction

Urinary tract infection (UTI) is the second most common infectious presentation in the community practices. Around 50% of women experience at least one episode of UTI at some point in their lifetime. Recurrent UTIs (rUTIs) occur in 20-40% of women. European Association of Urology (EAU) guidelines have suggested that, antimicrobial prophylaxis for prevention of rUTI should be considered only after counselling and behavioural modification has been attempted and when non-antimicrobial measures have been unsuccessful.

CRANFIT (a combination of cranberry and D-mannose) is one such non-antimicrobial solution for the prevention of rUTIs. 

1. What is CRANFIT?

CRANFIT tablets are composed of a combination of cranberry extract and D-mannose. It helps in promoting urinary tract health and may help to reduce the frequency of UTIs.

Composition:

Each serving (approx. 1.185 g film-coated) tablet contains:

D-mannose…………………………………………………………600 mg

Cranberry Extract (25% Proanthocyanidins)……………………300 mg

Nutritional Information (Approximate Values)

Energy ………………………………………………………………2.4 kcal

Protein…………………………………………………………….....0.00 g

Carbohydrate………………………………………………………..0.60 g

(Sugar………………………………………………………………..0.00 g)

Fat…………………………………………………………………….0.00 g

2. How does CRANFIT work?

  • E.coli is the most common bacteria causing UTI and has hair-like protruding fimbria on their surface through which it attaches to the surface of urinary tract.
  • Cranberry contains proanthocyanidins (PAC) which binds to the mannose-resistant adhesins (P-fimbriae) of E.coli and inhibit the binding of this bacteria to urinary tract.
  • D-mannose binds to the mannose-sensitive type 1 pili of E.coli bacteria thereby, blocking its attachment to the surface of urinary tract.

3. What is the dosage of CRANFIT tablets?

Dosage recommendations of cranberry products in the prevention of UTI have been poorly defined. The recommended doses of cranberry extract range from 600 to >1200 mg/day divided into 2 to 3 daily doses. The recent randomized placebo-controlled study have shown that, 2 g D-mannose once daily is as effective as 50 mg nitrofurantoin in preventing rUTI.

Considering the above fact, the recommended dose of Cranfit tablets is one tablet thrice daily for the prophylaxis of rUTIs that will provide daily requirement of cranberry as 0.9 g (225 mg PAC) and D-mannose as 1.8 g.

4. What are the important warnings associated with the use of CRANFIT?

  • Cranberry is contraindicated in patients with renal impairment.
  • Cranberry should be used with caution in patients with known nephrolithiasis as cranberry contains moderate amount of oxalate.
  • There is no direct evidence of safety or harm to the mother and foetus on cranberry consumption during pregnancy has been reported.
  • In the clinical studies of D-mannose, patients with following conditions were excluded.
  • Symptoms of upper urinary tract infection and/or temperature >38°C
  • History of urinary tract anomalies
  • Diabetes
  • Pregnancy
  • A potentially clinical important drug-drug interaction exist between cranberry and warfarin. Increase in international normalized ratio (INR) of prothrombin time was reported in 

5. What are the common side effects of CRANFIT?

Most commonly reported adverse events include mild gastrointestinal upset such as nausea, vomiting, diarrhoea and gastric reflux.

June 2016